Beigene Ltd represents values of scientific innovation, patient-centricity, and global collaboration. With a strong corporate philosophy, Beigene prioritizes the discovery and development of innovative medicines to address unmet medical needs. They aim to improve patient outcomes by advancing targeted therapies and immunotherapies. Beigene believes in collaboration with academic institutions, industry partners, and healthcare stakeholders to accelerate scientific breakthroughs and improve healthcare worldwide. By embracing a patient-centric approach, Beigene strives to provide accessible treatments and optimal care. Overall, Beigene Ltd demonstrates a commitment to scientific advancement, patient well-being, and global partnerships in their mission to transform the lives of patients with cancer and other serious diseases.

Beigene Ltd is primarily present in several countries and regions. The company has a significant presence in China, where it is headquartered and operates various research and development facilities. Additionally, Beigene Ltd has expanded its reach and established a global presence by conducting clinical trials and collaborations in countries such as the United States, Australia, Canada, and certain European countries. With its focus on biopharmaceuticals, Beigene Ltd strives to enhance cancer treatment options and improve the lives of patients worldwide through its presence in multiple countries and regions around the globe.

Beigene Ltd has achieved several significant milestones. In December 2015, the company secured a collaboration agreement with Celgene Corporation for the development and commercialization of cancer treatments in China. This partnership marked a major milestone in Beigene's efforts to provide innovative therapies to Chinese patients. In 2017, Beigene obtained its first drug approval in China for BTK inhibitor Brukinsa, offering a targeted treatment for certain types of lymphoma. Another important milestone was the successful completion of IPOs on both the Hong Kong and Nasdaq stock exchanges in 2018, which provided Beigene with additional financial resources to advance its pipeline.

BeiGene Ltd is a renowned pharmaceutical company founded in 2010 in Beijing, China. The company focuses on developing and commercializing innovative medicines to meet various unmet medical needs globally. BeiGene's commitment lies in advancing breakthrough science and technologies to improve patients' lives. Since its establishment, the company has achieved significant milestones, including numerous successful clinical trials, regulatory approvals, and strategic collaborations. With a passionate team and robust pipeline, BeiGene is dedicated to discovering, developing, manufacturing, and commercializing high-quality medicines to address various diseases and improve healthcare outcomes worldwide.

The main competitors of Beigene Ltd in the market include multinational pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Merck & Co., and Novartis. These companies are also involved in developing and commercializing innovative medicines and therapies. Beigene Ltd faces competition in various therapeutic areas, including oncology and immuno-oncology, where it strives to excel through its research and development efforts and strategic partnerships. Ultimately, Beigene Ltd aims to establish a strong presence and gain a competitive edge in the global biopharmaceutical industry.

Beigene Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of Beigene Ltd is focused on developing and commercializing innovative oncology drugs. As a leading biotechnology company, Beigene aims to discover and develop high-quality therapies to address unmet medical needs in the field of cancer. By leveraging its expertise in drug discovery, clinical development, and commercialization, Beigene strives to improve patient outcomes and transform the lives of people affected by cancer. Through strategic collaborations, partnerships, and a diversified product pipeline, Beigene is committed to advancing novel therapies that can make a significant impact on cancer treatment.

Beigene KGV ir -11,41.

Beigene KUV ir 5,26.

AlleAktien kvalitātes vērtējums Beigene ir 3/10.

gaidāmā Beigene apgrozījums ir 22,86 miljardi USD.

gaidāmā Beigene peļņa ir -10,53 miljardi USD.

Beigene Ltd is a biotechnology company aimed at developing and commercializing innovative cancer therapies. The company was founded in 2010 and is headquartered in Beijing, China. Beigene specializes in the discovery, development, and commercialization of cancer drugs and has built an extensive portfolio of medications in recent years. Beigene's business model includes five main components. Firstly, the company conducts extensive research and development in all aspects of cancer treatment. It employs a variety of experts in its production facilities in China and the United States to develop drugs for different types of cancer. The company particularly focuses on developing drugs for solid tumors, hematological malignancies, and cancer immunotherapies. Secondly, Beigene collaborates with various players in the biotechnology industry to further develop its products and research. The company has established partnerships with leading universities, research institutions, and other companies in the industry. These partnerships have helped expand the company's portfolio and strengthen its ability to develop new cancer medications. Thirdly, Beigene has launched a wide range of cancer drugs that can be used to combat tumors in various types of cancer. Beigene has a number of medications in different phases of clinical trials, including already approved therapies for cancer. In addition to its own drug candidates, Beigene also works with partners to strengthen its pipeline and make progress in developing new cancer therapies both in China and overseas. Fourthly, Beigene has also presented opportunities for partnerships to commercialize its cancer drugs. The company has worked with some of the top pharmaceutical companies worldwide to bring some of its cancer medications to other countries. Beigene will enter into agreements and transfer licensing rights to other pharmaceutical companies to establish partnerships and ensure optimal commercialization of its medications. Fifthly, Beigene has excellent leaders and employees who support the company in achieving its goals. Since its founding, the company has experienced significant growth and has consistently engaged in innovative research and development. Furthermore, the company has followed a specific path in marketing its medications to achieve global reach as much as possible. Overall, Beigene's business model is a combination of intensive research and development, collaboration with other players in the industry, commercialization of cancer drugs, and outstanding personnel. The company is on track to become a key player in the field of cancer therapies and potentially contribute to finding a cure through its great success.

Beigene izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Beigene vai uzņēmums nedod dividendes.

Beigene ISIN ir KYG1146Y1017.

Beigene WKN ir A144EN.

Beigene simbols ir 6160.HK.

Pēdējo 12 mēnešu laikā Beigene maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Beigene plāno maksāt dividendes 0 USD apmērā.

Beigene pašreizējā dividendu rentabilitāte ir .

Beigene maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Beigene pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Beigene tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Beigene apmērā 0 USD, kas tika izmaksāta 7.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.07.2024..

Pēdējās dividendes izmaksa notika 7.07.2024..

Gadā 2023, Beigene izmaksāja 0 USD dividendes.

Beigene dividendes tiek izmaksātas USD.